Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34654791)
Watch
English
Inhibition of HSP90 molecular chaperones: moving into the clinic
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
title
Inhibition of HSP90 molecular chaperones: moving into the clinic
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
main subject
molecular chaperones
0 references
author
Rocío García-Carbonero
object named as
Rocio Garcia-Carbonero
series ordinal
1
0 references
Amancio Carnero
object named as
Amancio Carnero
series ordinal
2
0 references
author name string
Luis Paz-Ares
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
publication date
1 August 2013
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
volume
14
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
page(s)
e358-69
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
issue
9
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
cites work
Sick chaperones, cellular stress, and disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitors of the heat shock response: biology and pharmacology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HSP90 and the chaperoning of cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hsp90 molecular chaperone inhibitors: are we there yet?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Targeting HSP90 for cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Stable association of hsp90 and p23, but Not hsp70, with active human telomerase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association of NASP with HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and transport of linker histones into nuclei
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclophilin-40: evidence for a dimeric complex with hsp90.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hop modulates Hsp70/Hsp90 interactions in protein folding
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hsp90 inhibitors as promising agents for radiotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High HSP90 expression is associated with decreased survival in breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(13)70169-4
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
PubMed ID
23896275
1 reference
stated in
Europe PubMed Central
PubMed ID
23896275
retrieved
3 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit